Author
@DeepValuePlay DeepValuePlay
grade Bx.com/DeepValuePlay ↗
Concentrated deep-value micro-cap picker with explicit targets and candid risk disclosure
Posts mostly reply-thread theses on a handful of small/micro
trader score
-0.70
hit rate
43%
mean α
-3.10%
signals 14d
5
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 7 scored bets: 43% hit rate, -3.10% mean alpha, trader score -0.70. Their last-14d mentions, direction-adjusted, have moved -6.7% since posting (mean over 5 mentions with price data).
Recent signals5receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-15 | LQDA | @DeepValuePlay | +0.68 | Defends LQDA's launch and argues its 20% decline lacks a fundamental negative catalyst. | -9.1% | tweet ↗ |
| 2026-08-14 | LQDA | @DeepValuePlay | +0.60 | Argues Yutrepia should clear exclusivity issues and ultimately obtain FDA approval. | -9.1% | tweet ↗ |
| 2026-08-14 | UTHR | @DeepValuePlay | -0.25 | Argues Yutrepia should clear exclusivity issues and ultimately obtain FDA approval. | +3.1% | tweet ↗ |
| 2026-08-14 | LQDA | @DeepValuePlay | +0.65 | Says Yutrepia's dosing and side-effect profile should overcome UTHR exclusivity despite likely litigation. | -9.1% | tweet ↗ |
| 2026-08-14 | UTHR | @DeepValuePlay | -0.25 | Says Yutrepia's dosing and side-effect profile should overcome UTHR exclusivity despite likely litigation. | +3.1% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.